At this point, Amarin (Nasdaq: AMRN ) investors are used to hearing about delays from the Food and Drug Administration concerning Vascepa's NCE status -- but today they were faced with a delay of a different kind.
Amarin originally stated that it would make the decision whether to get a Vascepa sales team together toward the end of November, but the company recently announced that it's not yet ready to commit. The decision will now be deferred to the first half of December, but Amarin is still eyeing a drug launch in the early part of 2013.
Health care analysts Max Macaluso and David Williamson discuss this news and possible scenarios for Amarin in the following video.
The biotech space can make or break investors overnight, and while Amarin might not disappear into thin air without NCE status for Vascepa, the drug's success is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with top Fool.com analyst Max Macaluso's premium research report. Click here now to keep reading.